NR3C1 and Duchenne muscular dystrophy: To exert its pharmacological effect, DFZ acts as corticosteroid hormone receptor agonist, exploiting the high binding affinity for tissue glucocorticoid receptors.7 Very recently, DFZ was approved8 by the FDA (trade name: Emflaza) for its use in treatment of Duchenne Muscular Dystrophy (DMD), a genetic disorder that affects 1/3600 infants worldwide.